ArticleBone marrow transplantation2011
The EBMT activity survey 2008: impact of team size, team density and new trends.
Article in Bone marrow transplantation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.Transfusion · 2014Trial
- Intensification of GVHD prophylaxis with low-dose ATG-F before allogeneic PBSC transplantation from HLA-identical siblings in adult patients with hematological malignancies: results from a retrospective analysis.Bone marrow transplantation · 2012Trial
- Impact of center volume on acute graft versus host disease in allogeneic stem cell transplant recipients.International journal of hematology · 2025Article
- The paradox of haematopoietic cell transplant in Latin America.Bone marrow transplantation · 2021Article
- The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies.Bone marrow transplantation · 2019Article
- Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report.Bone marrow transplantation · 2018Article
- Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report.Bone marrow transplantation · 2017Article
- Differences in stem cell transplantation activity among regions in Spain: an economic explanation.Bone marrow transplantation · 2016Article
- Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually.Bone marrow transplantation · 2016Article
- Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants.Bone marrow transplantation · 2015Article
- Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis.Leukemia · 2014Article
- Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation.Bone marrow transplantation · 2014Article
- Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation.Bone marrow transplantation · 2014Article
- Hematopoietic SCT in Europe: data and trends in 2011.Bone marrow transplantation · 2013Article
- Article
- The EBMT activity survey: 1990-2010.Bone marrow transplantation · 2012Article
- Article
- Article
- Incidence and mortality trends of leukemia and lymphoma in Croatia, 1988-2009.Croatian medical journal · 2012Article
- New strategies for stem cell mobilization.Mediterranean journal of hematology and infectious diseases · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Six hundred and fifteen centers from 45 countries reported a total 30,293 HSCT to this 2008 EBMT survey with 26,810 first transplants (40% allogeneic, 60% autologous). This corresponds to an increase of 7% for the allogeneic and 3% for the autologous HSCT. Main indications were leukemias (32%; 89% allogeneic); lymphomas (56%; 89% autologous); solid tumors (6%; 96% autologous); and non-malignant disorders (6%; 88% allogeneic). There were more unrelated than HLA-identical sibling donors (49 vs 46%). The proportion of peripheral blood transplants remained stable with 99% for autologous and 70% for allogeneic HSCT. One fifth of the teams with >80 HSCT performed more than half of all HSCT. This trend towards teams with higher numbers of HSCT was stronger for allogeneic (Gini coefficient 57%) than for autologous HSCT (Gini coefficient 38%). Transplant rates (number of transplants per 10 million inhabitants) increased in a close to linear way with increasing team density (number of transplant teams per 10 million inhabitants) and without saturation (R(2)=0.54); this connection was even stronger for allogeneic HSCT (R(2)=0.67). These data illustrate status and trends for HSCT in Europe. They provide a rational basis for planning and patient counseling.
Indexed as
Identifiers
20348970What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.